#131489
Re: Farmas USA
AMRN
Saltó el stop a $4,5. La espero al cierre.
He encontrado esto... pero desconozco de quién están hablando y cuales son sus antecedentes. Habrá que hacer un poco de research.
https://seekingalpha.com/news/3771486-amarin-jumps-after-activist-sarissa-discloses-stake-in-13-f-filing
@nachete96 , sobre Prepare-It 2:
“Icosapent Ethyl Versus Placebo In Outpatients With COVID-19: The Main Results Of PREPARE-IT 2”
Highlights: These data represent the first presentation of the topline results from the PREPARE-IT 2 study, which was an investigator-initiated trial (IIT) to evaluate the efficacy of icosapent ethyl (IPE) to reduce hospitalizations or death in approximately 2000 patients in Argentina with a positive diagnosis for the COVID-19 virus. In this study, subjects were randomized 1:1 to receive IPE or placebo and received a loading dose of 8g per day of IPE for the first three days followed by 4g per day of IPE thereafter from days 4-28. The primary endpoint is COVID-19 related hospitalizations or death assessed through day 28.
Saltó el stop a $4,5. La espero al cierre.
He encontrado esto... pero desconozco de quién están hablando y cuales son sus antecedentes. Habrá que hacer un poco de research.
https://seekingalpha.com/news/3771486-amarin-jumps-after-activist-sarissa-discloses-stake-in-13-f-filing
“Icosapent Ethyl Versus Placebo In Outpatients With COVID-19: The Main Results Of PREPARE-IT 2”
Highlights: These data represent the first presentation of the topline results from the PREPARE-IT 2 study, which was an investigator-initiated trial (IIT) to evaluate the efficacy of icosapent ethyl (IPE) to reduce hospitalizations or death in approximately 2000 patients in Argentina with a positive diagnosis for the COVID-19 virus. In this study, subjects were randomized 1:1 to receive IPE or placebo and received a loading dose of 8g per day of IPE for the first three days followed by 4g per day of IPE thereafter from days 4-28. The primary endpoint is COVID-19 related hospitalizations or death assessed through day 28.
While the results of the PREPARE-IT 2 study in Argentina did not meet the primary and/or other endpoints studied, we believe it is valuable for Amarin to support pilot IITs of this nature to determine the safety and potential efficacy of VASCEPA/VAZKEPA in a diverse group of at-risk populations. Importantly, the study supports the safety and tolerability of VASCEPA/VAZKEPA at varying doses.
